CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
StemSight is developing stem cell therapies to treat blindness, specifically targeting limbal stem cell deficiency. By utilizing induced pluripotent stem cells, they aim to provide high-quality corneal tissue products to address the shortage of donor tissue.
StemSight is developing off-the-shelf stem cell therapies to cure blindness.
We aim to solve the global shortage of corneal donor tissue by producing high-quality tissue products using allogeneic induced pluripotent stem cells (iPSCs) and biomaterials.
Our lead product is aimed at a rare but severe form of corneal blindness, limbal stem cell deficiency (LSCD), for which there are currently no valid treatment options.
The company's innovations have arisen from extensive academic research, and the…
STEMSIGHT OY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
